Home/ Stocks/ JBIO

Jade Biosciences, Inc. Common Stock

JBIO XNAS

$21.96 +0.04 (+0.18%) ▲ 15-min delayed

Open

$22.76

High

$23.00

Low

$21.73

Volume

481.2K

Market Cap

$1.35B

About Jade Biosciences, Inc. Common Stock

Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 55 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-40,368,000	$-0.57
FY 2025	$0	$-127,410,000	$-3.19
Q3 2025	$0	$-25,175,000	$-0.48
Q4 2025	$0	$-31,932,000	$-0.11

Related Market News

No specific coverage for JBIO yet. Check out our latest market news or earnings calendar.

Get JBIO Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Jade Biosciences, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.